Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 1.00 |
| ▸ | HTR2A | P28223 | 9/20 | 1.00 |
| ▸ | HTR1A | P08908 | 7/20 | 1.00 |
| ▸ | HTR2B | P41595 | 6/20 | 1.00 |
| ▸ | HTR1D | P28221 | 3/20 | 1.00 |
| ▸ | HTR1B | P28222 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.80 |
| ▸ | BLM | P54132 | 2/20 | 0.80 |
| ▸ | HTR7 | P34969 | 3/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29389055 | 1.00 | HTR2C (1.00) | HTR2CHTR2AHTR1AHTR2BHTR1D | |
| Fumaric Acid SCHEMBL1321608 | 0.89 | NPSR1 (1.00) | HTR2CHTR2AHTR1AHTR2BHTR1D | |
| Maleic Acid SCHEMBL1321599 | 0.89 | NPSR1 (1.00) | HTR2CHTR2AHTR1AHTR2BHTR1D | |
| SCHEMBL22892464 | 0.89 | HTR2C (0.80) | HTR2CHTR2AHTR1AHTR2BHTR1D | |
| SCHEMBL24451374 | 0.87 | HTR2A (0.77) | HTR2CHTR2AHTR1AHTR2BHTR1D | |
| SCHEMBL17640312 | 0.87 | HTR2A (0.77) | HTR2CHTR2AHTR1AHTR2BHTR1D | |
| SCHEMBL6981457 | 0.87 | HTR2C (0.77) | HTR2CHTR2AHTR1AHTR2BHTR1D | |
| SCHEMBL22538964 | 0.87 | HTR2C (0.76) | HTR2CHTR2AHTR1AHTR2BHTR1D | |
| SCHEMBL20340879 | 0.85 | HTR2A (0.74) | HTR2CHTR2AHTR1AHTR2BHTR1D | |
| SCHEMBL6710624 | 0.83 | HTR2C (0.71) | HTR2CHTR2AHTR1AHTR2BHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 391 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252535-A1 | CELLULAR COMPOSITION FOR TREATMENT OF DISEASES, DISORDERS OR CONDITIONS AND METHOD OF USE | YZTHERAPEUTIC PERFORMANCE LTD. (IL) | 2024-08-01 | — | — | US | claimed |
| EP-4208177-A1 | CELLULAR COMPOSITION FOR TREATMENT OF DISEASES, DISORDERS OR CONDITIONS AND METHOD OF USE | Yztherapeutic Performance Ltd. (IL) | 2023-07-12 | — | — | EP | claimed |
| US-20220249440-A1 | MUSCLE REGENERATION PROMOTER | SATO PHARMACEUTICAL CO., LTD. (JP) | 2022-08-11 | — | — | US | claimed |
| US-20110269141-A1 | TARGET PROTEIN AND TARGET GENE FOR DRUG DISCOVERY, AND SCREENING METHOD | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2011-11-03 | — | — | US | claimed |
| WO-2008141057-A1 | DEUTERATED PIMAVANSERIN 1- (4-FLU0R0BENZYL) -3- (4-ISOBUTOXYBENZYL) -1- ( L-METHYL-PIPERIDIN-4-YL) -UREA | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | claimed |
| WO-2008141033-A1 | SUBSTITUTED NAPHTHALENES | AUSPEX PHARMACEUTICALS INC. (US) | 2008-11-20 | — | — | WO | claimed |
| US-20080280991-A1 | SUBSTITUTED NAPHTHALENES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | claimed |
| US-20080280886-A1 | SUBSTITUTED UREAS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | claimed |
| US-20060281752-A1 | Method for the normalization of sexual response and amelioration of long term genital tissue degradation | HEATON JEREMY P W | 2006-12-14 | — | — | US | claimed |
| CN-1269484-C | Serotonergic 5HT2 agonists for treating glaucoma | ALCON LAB INC (US) | 2006-08-16 | — | — | CN | claimed |
| EP-1112106-A2 | SEROTONERGIC 5HT2 AGONISTS FOR TREATING GLAUCOMA | ALCON LABORATORIES, INC. (US) | 2001-07-04 | — | — | EP | claimed |
| EP-1096927-A1 | COMPOSITION FOR TREATMENT OF STRESS | Massachusetts Institute of Technology (US) | 2001-05-09 | — | — | EP | claimed |
| EP-1089736-A2 | METHOD AND COMPOSITIONS FOR THE TREATMENT OR AMELIORATION OF FEMALE SEXUAL DYSFUNCTION | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2001-04-11 | — | — | EP | claimed |
| EP-1083918-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE 5-HT RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-21 | — | — | EP | claimed |
| WO-2000016761-A2 | SEROTONERGIC 5HT2 AGONISTS FOR TREATING GLAUCOMA | ALCON LABORATORIES, INC. (US) | 2000-03-30 | — | — | WO | claimed |
| WO-2000003701-A1 | COMPOSITION FOR TREATMENT OF STRESS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-01-27 | — | — | WO | claimed |
| WO-1999066909-A2 | METHOD AND COMPOSITIONS FOR THE TREATMENT OR AMELIORATION OF FEMALE SEXUAL DYSFUNCTION | UNIV KINGSTON (CA) | 1999-12-29 | — | — | WO | claimed |
| WO-1999064044-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE 5-HT RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| US-5521183-A | Use of 5-HT ligands as anti-pruritic agents | ALLERGAN (US) | 1996-05-28 | — | — | US | claimed |
| WO-1996006601-A1 | USE OF 5-HT LIGANDS AS ANTI-PRURITIC AGENTS | ALLERGAN (US) | 1996-03-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220249440-A1 | MUSCLE REGENERATION PROMOTER | MUSK, MYLK2, MYH2 | HTR2C 72/4885HTR2A 28/4885HTR1A 20/4885 |
| US-20080280991-A1 | SUBSTITUTED NAPHTHALENES | MTNR1A, MTNR1B, TPH1 | HTR2C 8/4885HTR2A 6/4885HTR1A 4/4885 |
| US-20060281752-A1 | Method for the normalization of sexual response and amelioration of long term genital tissue degradation | OXTR, KISS1R, GNRHR | HTR2C 695/4885HTR2A 230/4885HTR1A 234/4885 |
| US-20080280886-A1 | SUBSTITUTED UREAS | HTR4, HTR5A, HTR6 | HTR2C 7/4885HTR2A 8/4885HTR1A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.